Market
Will Novo Nordisk integrate Catalent sites by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Novo Nordisk's official press releases or annual report
Story
Novo Nordisk Cleared to Acquire Three Catalent Manufacturing Sites for $CTLT Following FTC Approval
Dec 14, 2024, 08:49 AM
Novo Nordisk has received clearance to proceed with its acquisition of three manufacturing sites from Catalent, following the Federal Trade Commission's decision not to challenge the deal. This acquisition is part of a larger transaction involving Catalent and Novo Holdings, which has also met all regulatory closing conditions. The approval allows Novo Nordisk to enhance its manufacturing capabilities by integrating these sites, thereby strengthening its position in the pharmaceutical sector. The deal has been noted as significant given the current regulatory environment surrounding pharmaceutical acquisitions.
View original story
Similar markets
Significantly increase • 25%
Decrease • 25%
No change • 25%
Slightly increase • 25%
Partner with another company • 25%
Discontinue development • 25%
Submit for regulatory approval • 25%
Seek further trials • 25%
Haemophilia and multiple other product types • 25%
Haemophilia and one other product type • 25%
No production • 25%
Only haemophilia products • 25%
Significant increase • 25%
No significant change • 25%
Decrease • 25%
Moderate increase • 25%